MedTrace Logo

Phase 1, Multiple Dose Study of MPC-6827 in Subjects With Refractory Solid Tumors

NCT00394446 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 48

Last updated 2008-02-13

No results posted yet for this study

Summary

Phase 1, Multiple Dose Study of MPC-6827 in Subjects with Refractory Solid Tumors.

Conditions

  • Refractory Solid Tumors

Interventions

DRUG

MPC-6827

2-hour intravenous infusion given once weekly for 3 consecutive weeks on a 28 day cycle

Sponsors & Collaborators

  • Myrexis Inc.

    lead INDUSTRY

Principal Investigators

  • Margaret Yu, MD · Myrexis Inc.

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2005-03-31
Primary Completion
2007-04-30
Completion
2008-02-29

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00394446 on ClinicalTrials.gov